Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma

Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, View ORCID ProfileChing-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
doi: https://doi.org/10.1101/2022.10.03.510561
Xiaodan Qin
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Lam
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Zhang
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
2Guangdong Key Laboratory for Innovative Development and Utilization of Forest Plant Germplasm, College of Forestry and Landscape Architecture, South China Agricultural University, Guangzhou, Guangdong, CN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satyaki Sengupta
3Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Bryan Iorgulescu
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
5Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Zuo
6Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander E. Floru
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Meara
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Lin
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Lloyd
7Institute for Protein Innovation, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Kwok
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaylee Smith
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raghavendar T. Nagaraju
8Faculty of Biology, Medicine and Health, Division of Cancer Sciences, University of Manchester, Manchester, England, UK
9Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob Meijers
7Institute for Protein Innovation, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Ceol
10Department of Molecular Cell, and Cancer Biology, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Ti Liu
11Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ching-Ti Liu
Sanda Alexandrescu
12Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine J. Wu
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
13Department of Medicine, Brigham and Women’s Hospital, Boston, Harvard Medical School, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derin B. Keskin
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
14Translational Immunogenomics Laboratory, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
15Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
16Department of Computer Science, Metropolitan College, Boston University, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rani E. George
3Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Feng
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: huifeng@bu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Solid tumors, especially those with aberrant MYCN activation, harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance1,2, yet the underlying mechanisms are elusive and effective strategies to tackle this challenge are lacking. Here we demonstrated the crucial role of T regulatory (Treg) cells in MYCN-mediated immune repression and tumor aggression using high-risk neuroblastoma (NB) as a model system. Human MYCN-activated NB attracts CD4+ Treg cells, which are also found enriched in MYCN-high primary patient samples. Zebrafish MYCN-overexpressing neural crests recruit Cd4+ cells before tumor formation and induce an immunosuppressive microenvironment, thereby promoting tumor onset and progression. Strikingly, disruption of Treg cells through depletion of forkhead box protein 3a restores anti-tumor immunity and impairs NB development. Together, our studies establish Treg cells as the key driver of MYCN-mediated immunosuppression and tumor aggressiveness, providing mechanistic insights and therapeutic implications.

Competing Interest Statement

D.B.K owns equity in Affimed NV., Agenus Bio., Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Celldex Therapeutics, Clovis Oncology, Editas Medicine, Exelixis, Gilead Sciences, Immunitybio, ImmunoGen, I.M.V., Lexicon Pharmaceuticals, Moderna, Neoleukin Therapeutics, and Regeneron Pharmaceuticals.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 05, 2022.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, Ching-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
bioRxiv 2022.10.03.510561; doi: https://doi.org/10.1101/2022.10.03.510561
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, Ching-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
bioRxiv 2022.10.03.510561; doi: https://doi.org/10.1101/2022.10.03.510561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cancer Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4397)
  • Biochemistry (9632)
  • Bioengineering (7123)
  • Bioinformatics (24940)
  • Biophysics (12671)
  • Cancer Biology (9998)
  • Cell Biology (14405)
  • Clinical Trials (138)
  • Developmental Biology (7989)
  • Ecology (12148)
  • Epidemiology (2067)
  • Evolutionary Biology (16026)
  • Genetics (10953)
  • Genomics (14778)
  • Immunology (9907)
  • Microbiology (23739)
  • Molecular Biology (9508)
  • Neuroscience (51056)
  • Paleontology (370)
  • Pathology (1545)
  • Pharmacology and Toxicology (2694)
  • Physiology (4038)
  • Plant Biology (8696)
  • Scientific Communication and Education (1512)
  • Synthetic Biology (2404)
  • Systems Biology (6459)
  • Zoology (1350)